dc.creatorSousa, Taís Nóbrega de
dc.creatorKano, Flora Satiko
dc.creatorBrito, Cristiana Ferreira Alves de
dc.creatorCarvalho, Luzia Helena
dc.date2015-03-02T17:30:52Z
dc.date2015-03-02T17:30:52Z
dc.date2014
dc.date.accessioned2023-09-26T22:19:44Z
dc.date.available2023-09-26T22:19:44Z
dc.identifierSOUSA, Taís Nóbrega de et al . The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon. Mem. Inst. Oswaldo Cruz, v. 109, n. 5, pp. 608-617, 2014.
dc.identifier0074-0276
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/9582
dc.identifier10.1590/0074-0276130592.
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8877911
dc.descriptionPlasmodium vivax infects human erythrocytes through a major pathway that requires interaction between an apical parasite protein, the Duffy binding protein (PvDBP) and its receptor on reticulocytes, the Duffy antigen/receptor for chemokines (DARC). The importance of the interaction between PvDBP (region II, DBPII) and DARC to P. vivax infection has motivated our malaria research group at Oswaldo Cruz Foundation (state of Minas Gerais, Brazil) to conduct a number of immunoepidemiological studies to characterise the naturally acquired immunity to PvDBP in populations living in the Amazon rainforest. In this review, we provide an update on the immunology and molecular epidemiology of PvDBP in the Brazilian Amazon - an area of markedly unstable malaria transmission - and compare it with data from other parts of Latin America, as well as Asia and Oceania.
dc.formatapplication/pdf
dc.languageeng
dc.publisherFundação Oswaldo Cruz
dc.rightsopen access
dc.subjectmalaria
dc.subjectPlasmodium vivax
dc.subjectDuffy binding protein
dc.subjectnaturally acquired antibodies
dc.subjectgenetic variability
dc.titleThe Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon
dc.typeArticle


Este ítem pertenece a la siguiente institución